Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Resverlogix Corp. (TSX: RVX) - Donald McCaffrey, President & CEO speaks about the late-stage biotechnology company and their flagship drug - Apabetalone.
Cannot view this video? Visit:
https://b-tv.com/resverlogix-the-future-of-drug-development-btv-investing-news/
Resverlogix Corp. (TSX: RVX)
About Resverlogix Corp.:
Resverlogix is developing Apabetalone, a first-in-class, epigenetic therapeutic candidate for the potential treatment of COVID-19 and vascular diseases. It is a selective BET (bromodomain and extra-terminal) inhibitor targeting one specific domain in contrast to other experimental multi-domain BET inhibitors. Apabetalone works in preventing and treating disease progression by regulating the expression of disease-causing genes.
About CEO Clips:
CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. These 90 second video profiles broadcast on national TV and online via 12 financial sites including: Thomson Reuters, Bloomberg, Yahoo! Finance and Stockhouse.com.
BTV - Business Television/CEO Clips
Discover Companies to Invest in
Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/107856
